Table 2. Characteristics and allergy test results eperisone anaphylactic patients in a single pharmacovigilance center (n = 11).

No.	Age/sex	Initial co-administered drugs with eperisone	SPT	BAT	Tryptase	OPT	Dose* (mg)	Time† (min)	Symptom and signs of OPT
1	60/F	Aceclofenac, others‡	ND	ND	8.53	Pos	25	55	Shock, generalized pruritis, chest discomfort
2	64/F	Loxoprofen, others‡	ND	ND	ND	Pos	50	60	Dyspnea, urticaria
3	51/M	Aceclofenac, tramadol	ND	ND	ND	Pos	50	60	Shock, urticaria, angioedema
4	45/M	Others‡	ND	ND	ND	Pos	5	30	Dyspnea, urticaria, angioedema
5	56/F	Acetaminophen, tramadol, others‡	ND	ND	3.23	Pos	25	60	Generalized urticaria
6	32/M	Aceclofenac, others‡	Neg	Neg	15.5	Pos	5	15	Shock, angioedema, chest discomfort, dysphagia
7	70/F	Loxoprofen	Neg	Neg	ND	Pos	5	10	Urticaria, dyspnea, chest discomfort, angioedema
8	50/F	Aceclofenac, others‡	ND	ND	ND	Pos	15	30	Shock, desaturation, urticaria
9	62/F	Loxoprofen, others‡	ND	ND	ND	Pos	15	210	Generalized rash
10	59/F	Loxoprofen, acetaminophen, tramadol, others‡	Neg	Neg	ND	Pos	5	30	Dyspnea, urticaria, angioedema, chest discomfort
11	59/F	Aceclofenac, others‡	Neg	Neg	ND	Pos	15	90	Shock, angioedema, dyspnea

M, male; F, female; SPT, skin prick test; BAT, basophil activation test; OPT, oral provocation test; ND, not done; Neg, negative reaction; Pos, positive reaction.

^*Cumulative dose for positive reaction during OPT; ^†Onset time of positive reaction during OPT; ^‡Others are gastrointestinal protective drugs such as rebamipide, almagate, or ranitidine.